Given the chondrocytic origin shared by osteoarthritis (OA) and CHS, and the central role of PAR-2 in tumorigenic inflammation and matrix degradation, this mechanistic axis represents a promising therapeutic target in CHS. Here, LYST is linked to osteoarthritis.